Krystal Biotech, Inc. (KRYS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
Sabre Corporation SABR reported fourth-quarter 2024 adjusted loss of eight cents per share, wider than the Zacks Consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback